The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Next Generation Cancer Diagnostics Market Expected To Scale Between 2026 And 2030?
The next generation cancer diagnostics market size has experienced rapid expansion in recent years. This market is anticipated to expand from $14.4 billion in 2025 to $16.29 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.2%. Historically, this upward trend can be ascribed to factors including increasing cancer incidence rates, progress in genomic sequencing technologies, the growing clinical acceptance of biomarker-based diagnostics, an increase in oncology research funding, and a rising need for precision diagnostics.
The next generation cancer diagnostics market size is anticipated to undergo significant expansion over the upcoming years. It is forecast to achieve a valuation of $26.44 billion by 2030, advancing at a compound annual growth rate (CAGR) of 12.9%. The projected increase in this period can be ascribed to a heightened embrace of personalized medicine approaches, rising investments in advanced cancer screening programs, a growing reliance on minimally invasive diagnostic methods, the expansion of companion diagnostics development, and the increasing incorporation of AI-driven clinical decision support. Key trends identified for the forecast period include a greater adoption of liquid biopsy technologies, an increasing utilization of multi-omics diagnostic platforms, the expanding integration of AI-based cancer analytics, the broadening of personalized oncology diagnostics, and an amplified focus on early-stage cancer detection.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30336&type=smp
Which Factors Are Influencing The Growth Of The Next Generation Cancer Diagnostics Market?
The rising need for personalized medicines is anticipated to boost expansion within the next generation cancer diagnostics market in the future. These medicines are defined as medical treatments specifically designed for an individual’s unique genetic profile, way of life, and surroundings, aiming to deliver the most effective care for that particular patient. This growing demand stems from the increasing incidence of chronic and rare illnesses, which require specialized, patient-focused therapies to achieve better treatment results. Next generation cancer diagnostics facilitate personalized medicine by offering accurate molecular data, which helps in formulating customized treatment plans according to a patient’s distinct genetic and tumor characteristics. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit body, reported that the FDA granted approval to 16 new personalized therapies for rare disease patients in 2023, representing a significant increase from the six approvals seen in 2022. Consequently, the heightened need for personalized medicines is a key factor driving the expansion of the next generation cancer diagnostics market.
Which Segment Types Are Examined In The Next Generation Cancer Diagnostics Market Segment Study?
The next generation cancer diagnostics market covered in this report is segmented –
1) By Technology: Next-Generation Sequencing (NGS), Lab-On-A-Chip (LOAC) And Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR), Circulating Tumor Deoxyribonucleic Acid (ctDNA) Assays, Protein Microarrays, Deoxyribonucleic Acid Microarrays, Other Multi-Omics Platforms
2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer
3) By Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis
4) By Application: Biomarker Development, Circulating Tumor Cell (CTC) Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis
5) By End User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Pharmaceutical And Biotechnology Companies, Home Care Settings
Subsegments:
1) By Next-Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Transcriptome Sequencing
2) By Lab-On-A-Chip And Reverse Transcriptase-Polymerase Chain Reaction: Microfluidic Chip Assays, Integrated Reverse Transcriptase-Polymerase Chain Reaction Chips, Point-of-Care Lab-On-A-Chip Devices, High-Throughput Lab-On-A-Chip Systems
3) By Circulating Tumor Deoxyribonucleic Acid Assays: Single-Gene Circulating Tumor Deoxyribonucleic Acid Assays, Multi-Gene Circulating Tumor Deoxyribonucleic Acid Panels, Digital Droplet Circulating Tumor Deoxyribonucleic Acid Assays, Next-Generation Sequencing Circulating Tumor Deoxyribonucleic Acid Assays
4) By Protein Microarrays: Analytical Protein Microarrays, Functional Protein Microarrays, Reverse Phase Protein Microarrays, Antibody-Based Protein Microarrays
5) By Deoxyribonucleic Acid Microarrays: Gene Expression Deoxyribonucleic Acid Microarrays, Single Nucleotide Polymorphism Genotyping Deoxyribonucleic Acid Microarrays, Comparative Genomic Hybridization Deoxyribonucleic Acid Microarrays, Methylation Deoxyribonucleic Acid Microarrays
6) By Other Multi-Omics Platforms: Metabolomics Platforms, Epigenomics Platforms, Transcriptomics Platforms, Integrated Multi-Omics Systems
Which Trends Are Influencing Demand In The Next Generation Cancer Diagnostics Market?
Companies operating in the next generation cancer diagnostics market are concentrating on developing innovative solutions like artificial intelligence-driven multi-modal diagnostic platforms to improve early detection, personalized treatment, and clinical decision-making. These artificial intelligence-driven multi-modal diagnostic platforms are advanced systems that leverage artificial intelligence to integrate and analyze various biological data types, including genomic, proteomic, imaging, and clinical information, thereby providing more accurate and personalized cancer detection and diagnosis. For instance, in April 2025, OneCell Diagnostics Pvt Ltd., an India-based precision oncology company, launched OncoIncytes, a multi-modal cancer diagnostic platform specifically designed for precision oncology. This platform combines different data types, such as circulating tumor DNA, single-cell circulating tumor cells, RNA information, and detailed protein profiles of 150 proteins at the single-cell level. Utilizing a 1080-gene panel powered by AI and machine learning, OncoIncytes delivers highly sensitive and specific insights to enhance clinical trial outcomes, particularly in early-stage research and antibody-drug conjugate development. The platform enables personalized cancer detection, therapy monitoring, and drug development through non-invasive, real-time, and scalable diagnostics, all accessible via OneCell’s proprietary iDiscover application from a CLIA-certified laboratory.
Which Players Are Part Of The Competitive Landscape Of The Next Generation Cancer Diagnostics Market?
Major companies operating in the next generation cancer diagnostics market are F. Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Danaher Corporation, Koninklijke Philips N.V., General Electric Company, Becton, Dickinson and Company, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Almac Group Ltd., Natera Inc., Myriad Genetics Inc., NeoGenomics Inc., Guardant Health Inc., Freenome Holdings Inc., Personalis Inc., Burning Rock Biotech Limited., SOPHiA GENETICS S.A., Singlera Genomics Co. Ltd.
Get The Full Next Generation Cancer Diagnostics Market Report:
Which Region Represents The Largest Share Of The Next Generation Cancer Diagnostics Market?
North America was the largest region in the next generation cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Next Generation Cancer Diagnostics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Next Generation Cancer Diagnostics Market 2026, By The Business Research Company
Peripheral Neuropathy Market Report 2026
https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report
Chronic Pain Market Report
https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report
Neuralgia Treatment Market Report
https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model